Harnessing molecular metabolism through atomic-tagging technologies to enable precision measurement of biological flux activity across clinical diagnostics, translational research, and biotechnology as a new class of measurement.
IP established, July 2025.
International PCT, filed July 2026.
A coordinated, multi-site laboratory research program for feasibility and development of ISOKEM-X.
“Development of rapid, highly sensitive and specific clinical diagnostics that are easy to use, cost-effective, and can diagnose individuals infected with pathogens”
U.S. Patent Pending No. 19/270,779
International (PCT) No. PCT/US26/36378
Rapid, breath-based, point-of-care assessment of viable bacterial infection in vivo, designed to enable earlier diagnostic readout and support biologically aligned clinical decision-making.
U.S. Patent Pending No. 19/755,655
Rapid, point-of-care assessment of infected biologic samples across blood, urine, cerebrospinal fluid, bronchoalveolar lavage, peritoneal fluid, tissue suspensions, and other ex vivo biologic samples, designed to move infectious disease diagnostics beyond delayed culture, indirect biomarkers, and cohort-derived statistical inference.
U.S. Patent Pending No. 19/688,479
Continuous, real-time monitoring of pathway kinetics through direct measurement of enzymatic flux, designed to replace labor-intensive and destructive reconstruction workflows across laboratory research and industrial biotechnology.
